The phase 1b PRISM study is assessing the ability of ruxolitinib/retifanlimab to reinvigorate the tumor microenvironment in immune-resistant RCC.
Yu-Wei Chen, MD, MS
Advertisement
Articles by Yu-Wei Chen, MD, MS
Yu-Wei Chen, MD, MS, discussed research on ARNT expression patterns in RCC and potential implications for HIF-1β targeting therapies like NEO-811.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Why MRI Contrast Agents Are Not Interchangeable for Detecting Brain Metastases
2
FDA Gives Accelerated Approval to Sevabertinib in HER2+ NSCLC
3
Durvalumab Combo Improves Survival in First-Line Extensive-Stage SCLC
4
INBRX-106 Plus Pembrolizumab Nearly Doubles Response Rate in HNSCC
5